Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for SFOSF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SFOSF and 80,000+ other tickers.
See exactly how SFOSF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SFOSF and 80,000+ other tickers.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF), founded in 1994 and based in Shanghai, China, is a comprehensive pharmaceutical enterprise. The company is actively engaged in the research, development, manufacturing, and sale of pharmaceutical products, serving markets across Mainland China and internationally. Its diverse operations are structured into five main segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Services, Pharmaceutical Distribution and Retail, and Other Business activities. Within its pharmaceutical portfolio, Fosun Pharma…
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (OTCMKTS:SFOSF - Get Free Report) saw a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 1,192,172 shares, a growth of 21.2% from the January 15th total of 983,500 shares. Based on an average daily volume of 60 shares,
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
Genuine Biotech rec'd China approval on Monday for use of HIV drug in Covid-19 treatment
Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen's Bavarian Nordic in a $225 million deal.
Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese companies into mRNA vaccines and treatments.